Quick Answer
Annovis Bio, Inc. reported Net Income of -$28.85 million for fiscal year 2025.
Annovis Bio, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$28.85M -17.3% |
-$24.59M +56.2% |
-$56.20M -121.9% |
-$25.33M -74.8% |
-$14.49M -165.2% |
-$5.46M -451.2% |
| Diluted EPS | -$1.40 +39.4% |
-$2.31 +62.9% |
-$6.23 -101.0% |
-$3.10 -63.2% |
-$1.90 -118.4% |
-$0.87 |
| Total Assets | $21.08M +51.4% |
$13.93M +36.4% |
$10.21M -76.9% |
$44.10M -4.1% |
$46.00M +466.6% |
$8.12M +626.8% |
| Cash and Equivalents | $19.53M +85.1% |
$10.55M +83.4% |
$5.75M -86.5% |
$42.67M -6.6% |
$45.69M +465.8% |
$8.07M +434488.7% |
| Stockholders Equity | $16.85M +81.0% |
$9.31M +220.1% |
-$7.75M -118.2% |
$42.70M -4.0% |
$44.49M +490.0% |
$7.54M +187.9% |
| R&D Expense | $25.22M +26.1% |
$20.00M -48.5% |
$38.79M +134.9% |
$16.52M +94.8% |
$8.48M +177.6% |
$3.05M +293.4% |
| Operating Income | -$29.70M -11.2% |
-$26.69M +40.7% |
-$45.04M -76.5% |
-$25.51M -75.5% |
-$14.54M -118.9% |
-$6.64M -313.6% |
| Shares Outstanding | 27.20M +92.3% |
14.14M +34.4% |
10.52M +28.9% |
8.16M +0.8% |
8.10M +17.5% |
6.89M +2338.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$7.26M | +42.5% | -16.8% |
| Diluted EPS | September 30, 2025 | -$0.37 | +61.9% | -15.6% |
| Total Assets | September 30, 2025 | $17.19M | +19.7% | -19.9% |
| Cash and Equivalents | September 30, 2025 | $15.29M | +21.0% | -10.8% |
| Stockholders Equity | September 30, 2025 | $13.16M | +86.3% | -28.2% |
| R&D Expense | September 30, 2025 | $6.29M | +133.9% | +21.9% |
| Operating Income | September 30, 2025 | -$7.43M | -69.5% | -18.6% |
| Shares Outstanding | September 30, 2025 | 20.19M | +52.0% | +3.6% |
- Annovis Bio, Inc. reported Net Income of -$28.85 million for fiscal year 2025.
- Annovis Bio, Inc. showed a decrease of -17.3% in Net Income compared to the prior fiscal year.
- Annovis Bio, Inc. reported Diluted EPS of $1.40 per share (loss) for fiscal year 2025.
- Annovis Bio, Inc. showed an increase of +39.4% in Diluted EPS compared to the prior fiscal year.
- Annovis Bio, Inc. reported Total Assets of $21.08 million for fiscal year 2025.
- Annovis Bio, Inc. showed an increase of +51.4% in Total Assets compared to the prior fiscal year.
- Annovis Bio, Inc. reported Cash and Equivalents of $19.53 million for fiscal year 2025.
- Annovis Bio, Inc. showed an increase of +85.1% in Cash and Equivalents compared to the prior fiscal year.
- Annovis Bio, Inc. reported Stockholders Equity of $16.85 million for fiscal year 2025.
- Annovis Bio, Inc. showed an increase of +81.0% in Stockholders Equity compared to the prior fiscal year.
- Annovis Bio, Inc. reported R&D Expense of $25.22 million for fiscal year 2025.
- Annovis Bio, Inc. showed an increase of +26.1% in R&D Expense compared to the prior fiscal year.
- Annovis Bio, Inc. reported Operating Income of -$29.70 million for fiscal year 2025.
- Annovis Bio, Inc. showed a decrease of -11.2% in Operating Income compared to the prior fiscal year.
- Annovis Bio, Inc. reported Shares Outstanding of 27.20 million shares for fiscal year 2025.
- Annovis Bio, Inc. showed an increase of +92.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: